Trials / Completed
CompletedNCT02438644
Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina
Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (Erivedge) in Argentine patients. Only patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) will be considered in the effectiveness analysis. Study duration is estimated to be approximately 12 months.
Conditions
Timeline
- Start date
- 2015-06-30
- Primary completion
- 2017-07-26
- Completion
- 2017-07-26
- First posted
- 2015-05-08
- Last updated
- 2018-02-26
Source: ClinicalTrials.gov record NCT02438644. Inclusion in this directory is not an endorsement.